retatrutide patent expiration Last week's expiry of the for semaglutide—the active ingredient in Novo Nordisk's blockbuster drugs that are used to treat both diabetes and obesity—unleashed a flurry of launches of low-cost generic versions Top 12 Drug Patents Expiring

Philipose, et al., 'Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial', N

Despite promising preclinical studies, a 12-week clinical trial using an iteration of this initial dual-incretin agonist failed to demonstrate superiority relative to a GLP-1R monoagonist 15 , raising questions about multi-receptor strategies in humans

Many people prescribed GLP-1 receptor agonists for type 2 diabetes or weight management wonder whether they'll need to take these medications indefinitely

Retatrutide is investigational : as of this writing it has completed a landmark phase 2 trial and its sponsor has reported positive phase 3 topline results, but it is not approved by any regulator and is available only through clinical trials